Primary Chemotherapy for Resectable Breast Cancer
Primary (neoadjuvant, preoperative) chemotherapy for surgically curative breast cancer is a novel treatment approach. The sequentially combined strategy derives from prior experience achieved with locally advanced (stage III) disease in which primary chemotherapy including a regimen containing doxorubicin (Adriamycin) was delivered to achieve prompt tumor shrinkage and thus facilitate subsequent mastectomy and/or irradiation [1–4]. In recent years primary chemotherapy has been tested in resectable breast cancer with multifold clinical aims: (a) to increase the frequency of breast- saving procedures in tumors whose size would require mastectomy, (b) to decrease the frequency of local recurrence, and (c) to further improve relapse-free and total survival rates over those recently achieved with systemic adjuvant treatments [2, 5, 6] (the latter of these is reprinted in part in this volume). This paper summarizes and updates the clinical results of the prospective trial started in 1988 at the Milan Cancer Institute .
KeywordsToxicity Hepatitis Shrinkage Oncol Doxorubicin
Unable to display preview. Download preview PDF.
- 6.Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339:1–15, 71–85Google Scholar
- 11.Banzet P, Holland JF, Khayat D, Weil M (eds) (1991) Neoadjuvant chemotherapy. Springer, Berlin Heidelberg New YorkGoogle Scholar